Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables: 2020-2023

Historic Receivables for SAB Biotherapeutics (SABS) over the last 1 years, with Jun 2023 value amounting to $364,117.

  • SAB Biotherapeutics' Receivables fell 96.21% to $364,117 in Q2 2023 from the same period last year, while for Jun 2023 it was $19.6 million, marking a year-over-year decrease of 60.74%. This contributed to the annual value of $5.6 million for FY2022, which is 30.69% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Receivables of $364,117 as of Q2 2023, which was down 52.29% from $763,123 recorded in Q1 2023.
  • SAB Biotherapeutics' Receivables' 5-year high stood at $20.6 million during Q4 2020, with a 5-year trough of $364,117 in Q2 2023.
  • Over the past 3 years, SAB Biotherapeutics' median Receivables value was $8.0 million (recorded in 2021), while the average stood at $7.0 million.
  • Data for SAB Biotherapeutics' Receivables shows a maximum YoY crashed of 96.21% (in 2023) over the last 5 years.
  • SAB Biotherapeutics' Receivables (Quarterly) stood at $20.6 million in 2020, then plummeted by 61.04% to $8.0 million in 2021, then crashed by 30.69% to $5.6 million in 2022, then tumbled by 96.21% to $364,117 in 2023.
  • Its Receivables was $364,117 in Q2 2023, compared to $763,123 in Q1 2023 and $5.6 million in Q4 2022.